Medical cannabis by condition — the evidence-tier index

The clinical evidence base for cannabis as a therapy is uneven. Some conditions — chronic pain in adults, chemotherapy-induced nausea and vomiting, multiple sclerosis spasticity, certain pediatric epilepsy syndromes — have substantial evidence from randomized controlled trials, regulatory drug approvals, and consensus panels. Other conditions that qualify in most state medical programs (PTSD, anxiety disorders, several inflammatory diseases) have weaker or contradictory trial evidence even though patient-reported-outcome data is often supportive.

This hub is the browse-by-condition entry point for the mmjnow conditions library. It groups all 35 conditions in the library by clinical evidence strength, links to each condition's full hub, and points to the state-by-state qualifying status for each condition. The goal is to help patients, clinicians, and policy researchers move from "what does the evidence say" to "is this condition treatable here" in two clicks.

The evidence framework

mmjnow uses a four-tier evidence scale on every condition hub. The scale anchors on the 2017 National Academies of Sciences, Engineering, and Medicine consensus report The Health Effects of Cannabis and Cannabinoids, updated by NASEM in 2024 and reinforced by subsequent systematic reviews (IASP 2021 on chronic pain; Cochrane on cannabinoid-based medicines; National Cancer Institute PDQ; FDA prescribing information for approved cannabinoid drugs).

Strong evidence corresponds to NASEM's highest tier — conclusive or substantial evidence from multiple randomized controlled trials, meta-analyses, or regulatory drug-approval review.

Moderate evidence corresponds to NASEM's moderate tier — multiple supportive trials with consistent direction of effect, but smaller effect sizes, methodological limitations, or heterogeneity across studies.

Limited evidence corresponds to NASEM's limited tier — supportive patient-reported-outcome data and small trials, but no large randomized trial demonstrating disease-specific benefit beyond symptom relief.

Insufficient evidence corresponds to NASEM's "insufficient" tier — observational data only, or contradictory or null results from the small clinical-trial base.

Every mmjnow condition hub cites the specific evidence underpinning its tier and links to the underlying NASEM, FDA, NIH, or Cochrane source where one exists.

How to read the evidence tiers

Three operational points before the grid below.

First, evidence tiers describe the clinical research base, not the regulatory framework. Cannabis is Schedule I under federal law regardless of evidence tier; FDA-approved cannabinoid drugs are scheduled separately (dronabinol Schedule III; epidiolex Schedule V). A strong evidence tier does not imply federal medical legitimacy and does not change federal prohibitions on cannabis use by federal employees, clearance holders, or DOT-regulated workers. See the federal employment hub for the framework.

Second, evidence tiers and state qualifying-condition lists are independent. Many state medical-cannabis programs qualify conditions with limited or insufficient evidence (PTSD across most states; opioid use disorder in a growing minority; autism spectrum disorder in a handful) because state legislatures balance evidence with patient demand, advocacy, and alternative-therapy adequacy. Conversely, some conditions with stronger evidence are not on a state's statutory list. Each mmjnow condition hub shows both dimensions.

Third, the evidence base is dynamic. The 2024 NASEM update reaffirmed most 2017 findings; subsequent randomized trials and systematic reviews continue to refine specific conditions (notably chronic pain subtypes, sleep disturbance, pediatric epilepsy). The mmjnow editorial review cycle is quarterly; condition hubs carry visible last-reviewed dates.

The four-tier grid

The grid below is generated at build time from the mmjnow conditions collection. Every condition links to its hub with the full clinical summary, NASEM citation, FDA-approved cannabinoid drug information (where applicable), and the list of US states where the condition qualifies under each state's medical program.

Condition-by-state cross-references

Beyond the per-condition hubs linked in the grid, the mmjnow content graph includes a programmatic state-by-condition matrix at /states/<state-slug>/conditions/<condition-slug> that resolves the question "is condition X a qualifying condition in state Y?" with the state's status (listed, physician discretion, or not listed), the relevant statute citation, the clinical evidence summary, and the in-state registration steps. The full matrix is searchable via the site search at /search.

Evidence-tier movement and what's pending

Three conditions have moved tiers in the past 36 months based on accumulated trial data.

Refractory pediatric epilepsy (Dravet and Lennox-Gastaut syndromes) was already at NASEM's highest tier in 2017 based on the trials supporting the 2018 FDA approval of cannabidiol (Epidiolex). Subsequent post-marketing data has reinforced the finding. The tier remains "strong."

Cancer-related sleep disturbance moved from limited to moderate evidence in the 2024 NASEM update on the strength of subsequent trials in cancer-survivor populations. Cancer-related pain (covered under the broader "chronic pain in adults" finding) and chemotherapy-induced nausea and vomiting remain at the strong tier.

Chronic neuropathic pain in adults (a subset of "chronic pain in adults" in the 2017 framework) is now treated by several reviewers — the IASP 2021 position statement, the 2018 Cochrane review on cannabis-based medicines for chronic neuropathic pain — as a discrete and well-supported indication. The mmjnow chronic pain and peripheral neuropathy hubs reflect the neuropathic-pain subdivision.

Three conditions currently rated limited may move to moderate as randomized trials complete: post-traumatic stress disorder (currently several phase-2 trials with completion in 2026-2027); autism spectrum disorder (limited trials underway in pediatric and adolescent populations); endometriosis (no large randomized trial has completed; observational data is consistent).

When the evidence is insufficient

Conditions in the insufficient-evidence tier present a particular challenge. The state-qualifying-condition list often includes them — sometimes because of patient-advocacy pressure during program enactment, sometimes because the alternative therapies are inadequate, sometimes because of legislative compromise. Conditions in this category on mmjnow include several inflammatory and autoimmune diseases (lupus, rheumatoid arthritis with limited direct trial data), some psychiatric indications, and certain neurological disorders where the patient-reported-outcome literature is supportive but randomized-trial evidence has not accumulated.

The honest framing on the per-condition hub is the right one: when the evidence is insufficient, cannabis use should be considered as one option among several with realistic expectations and close clinical follow-up. The state qualifying-condition list reflects a policy judgment; the clinical evidence tier reflects what trials have demonstrated.

FDA-approved cannabinoid drugs and the prescription pathway

Independent of state medical cannabis programs, three FDA-approved cannabinoid drugs are available by prescription nationwide:

• Dronabinol (Marinol, Syndros) — synthetic THC, Schedule III. FDA-approved for chemotherapy-induced nausea and vomiting refractory to conventional antiemetics, and for AIDS-associated anorexia and weight loss. Prescribed under DEA Schedule III registration.
• Nabilone (Cesamet) — synthetic cannabinoid, Schedule II. FDA-approved for CINV refractory to conventional antiemetics.
• Cannabidiol (Epidiolex) — purified plant-derived CBD, Schedule V. FDA-approved for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients 1 year and older.

These are federal-controlled-substance prescriptions, not medical-cannabis-card products. They are available through any federally registered prescriber and dispensed by any pharmacy. They coexist with state medical cannabis programs: a cancer patient may receive prescribed dronabinol for CINV refractory to conventional antiemetics and separately participate in their state's medical cannabis program for additional symptomatic benefit.

The FDA has not approved plant cannabis or any full-spectrum cannabis product for any indication. State medical cannabis programs operate independent of FDA drug approval.

How clinicians use the evidence tiers

Cannabis-certifying clinicians work the evidence tier in three ways during the certification encounter.

As an inclusion filter. Conditions in the strong-evidence tier (chronic pain in adults, multiple sclerosis spasticity, CINV) are the easiest to certify. The clinician has substantial trial data and FDA-approved cannabinoid drugs in the same indication. The state qualifying-condition list will include these conditions almost universally; the clinical conversation focuses on dosing, route of administration, drug interactions, and monitoring rather than on whether cannabis is a reasonable consideration.

As a counseling anchor. Conditions in the moderate and limited tiers (PTSD, anxiety disorders, sleep disturbance in chronic pain, cancer-related symptoms beyond CINV) require a richer counseling conversation. The clinician anchors the discussion on what the trial evidence does and does not support: cannabis may help with reported symptoms but has not been shown in randomized trials to alter disease course or replace first-line therapies. Patient expectations are calibrated against the evidence.

As a research-flag. Conditions in the insufficient tier (some psychiatric indications, several inflammatory diseases, conditions where the trial evidence is contradictory) are flagged as research-frontier indications. Clinicians document the patient's other treatment history, set short follow-up intervals, and treat the certification as a trial of therapy rather than an established regimen.

The mmjnow per-condition hubs include a "How clinicians counsel" section that walks the evidence into the clinical conversation. For the broader clinician guidance framework see the editorial policy on medical-claim standards.

Drug interactions, contraindications, and special populations

Independent of the evidence tier, cannabis has a documented pharmacology that the prescribing clinician (or state-program-certifying clinician) must weigh against the patient's other medications and comorbidities.

CYP450 interactions. Cannabis and cannabinoids are metabolized primarily through CYP3A4 and CYP2C9. Drugs that inhibit these enzymes (clarithromycin, ketoconazole, ritonavir, some SSRIs) can increase cannabinoid blood levels. Drugs that induce them (rifampin, carbamazepine, phenytoin, St John's wort) can reduce cannabinoid blood levels. Cannabis itself can modify the metabolism of other CYP3A4 and CYP2C9 substrates. Cannabinoid-warfarin interaction is documented; INR monitoring is recommended for patients adding cannabis to warfarin.

Cardiovascular contraindications. Acute THC use produces dose-dependent tachycardia and modest blood-pressure changes. Patients with unstable angina, recent myocardial infarction, severe ventricular arrhythmia, or symptomatic hypotension are relative contraindications. The clinical guidance is consistent across cardiovascular specialty societies.

Psychiatric contraindications. First-episode psychosis, history of psychotic disorder, and family history of schizophrenia spectrum disorder are relative contraindications for high-THC products. The 2017 NASEM report rated the cannabis-schizophrenia association as substantial; the 2024 update reaffirmed.

Pediatric and adolescent use. Most state programs limit pediatric use to specific conditions (refractory epilepsy, severe autism in some states, terminal illness). The developmental neurobiology argument against routine pediatric or adolescent cannabis use is strong. FDA-approved pediatric cannabinoid use is limited to Epidiolex for specific epilepsy syndromes.

Pregnancy and lactation. Cannabis use during pregnancy is associated with lower birth weight and developmental concerns; consensus guidance across obstetrics specialty societies recommends abstention. Cannabis transfers into breast milk; pediatric guidance recommends abstention during lactation.

Geriatric considerations. Older adults are more sensitive to cannabinoid effects on cognition, balance, and orthostatic blood pressure. Initial dosing should be lower, titration slower, and monitoring closer.

The per-condition hubs detail population-specific guidance within the condition context.

Where the evidence base goes next

Three research trends will reshape the evidence tier table in the next five years.

The completion of several phase-2 and phase-3 randomized trials in PTSD and anxiety disorders will likely move at least one psychiatric indication from limited to moderate evidence. Trials underway through 2027 include the MAPS-funded MDMA-assisted-therapy parallel investigation of cannabis for PTSD and several smaller industry-sponsored trials.

The expansion of cannabinoid drug development beyond plant cannabis — selective CB1 and CB2 agonists, peripheral-only cannabinoid receptor modulators, fatty-acid amide hydrolase inhibitors — will produce evidence that may apply directly to plant cannabis indications or may diverge. The FDA-approved Epidiolex experience demonstrates that purified single-molecule cannabinoid drugs can succeed even when full-spectrum plant cannabis lacks the same evidence base.

The accumulation of real-world-evidence data from state medical cannabis registries (most prominently Minnesota's outcome-tracked program, Florida's state-administered registry) will increasingly inform clinical guidance. The 2024 NASEM update incorporated some real-world evidence; the 2027-2028 update is expected to lean more heavily.

The mmjnow editorial review cycle tracks these trends and updates condition-hub evidence tiers as the underlying trial data evolves.

Frequently asked questions

The five most-common questions about cannabis evidence tiers and state qualifying conditions are answered at the top of this hub (visible in the FAQ schema). For specific conditions see the individual hubs linked in the grid below. For the state-by-state qualifying status of each condition see the states index and each state's hub.